m	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
-3770	1:0,0,0,0
m-377c	1:0,0,0,0
now	1:0,0,0,0
supplied	1:0,0,0,0;1:0,0,0,0
the	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
intradermal	1:0,0,0,0;1:0,0,0,0
skin	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
test:	1:0,0,0,0;1:0,0,0,0
inject	1:0,0,0,0
into	1:0,0,0,0
(not	1:0,0,0,0
in	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
use	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
of	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
antistreptococcic	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
serum	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
concen	1:0,0,0,0
and	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
spreading	1:0,0,0,0
infections	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
with	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
marked	1:0,0,0,0;1:0,0,0,0
toxemia.	1:0,0,0,0
trated,	1:0,0,0,0
doses	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
should	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
be	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
one-third	1:0,0,0,0
or	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
one-fourth	1:0,0,0,0
under)	1:0,0,0,0
not	1:0,0,0,0
more	1:0,0,0,0
than	1:0,0,0,0
.02	1:0,0,0,0
(two	1:0,0,0,0
one-	1:0,0,0,0
rosenberg	1:0,0,0,0
nottley*	1:0,0,0,0
state	1:0,0,0,0
that	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
this	1:0,0,0,0
is	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
a	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
s	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
p	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
ntistreptococcic	1:0,0,0,0;1:0,0,0,0
erum	1:0,0,0,0;1:0,0,0,0
olyvalent	1:0,0,0,0
mvl	1:0,0,0,0
f	1:0,0,0,0;1:0,0,0,0
ord	1:0,0,0,0
dose	1:0,0,0,0
unconcentrated	1:0,0,0,0
serum.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
definite	1:0,0,0,0
value	1:0,0,0,0;1:0,0,0,0
treatment	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
streptococcus	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
hundredths)	1:0,0,0,0
cc.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
test	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
material.	1:0,0,0,0
evaluate	1:0,0,0,0
re'	1:0,0,0,0
syringe	1:0,0,0,0;1:0,0,0,0
package	1:0,0,0,0;1:0,0,0,0
meningitis	1:0,0,0,0
while	1:0,0,0,0
amoss	1:0,0,0,0
craven®	1:0,0,0,0
found	1:0,0,0,0;1:0,0,0,0
it	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
to	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
importance	1:0,0,0,0
large	1:0,0,0,0;1:0,0,0,0
strep	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
suit	1:0,0,0,0
10	1:0,0,0,0;1:0,0,0,0
minutes.	1:0,0,0,0
positive	1:0,0,0,0;1:0,0,0,0
reaction	1:0,0,0,0;1:0,0,0,0
consists	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
definitely	1:0,0,0,0
effective	1:0,0,0,0;1:0,0,0,0
hemolytic	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
50'012.	1:0,0,0,0
20'cc.	1:0,0,0,0
syringes	1:0,0,0,0
accessories.	1:0,0,0,0
n	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
t	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
r	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
e	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
o	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
c	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
tococcus	1:0,0,0,0
has	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
been	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
emphasized	1:0,0,0,0
by	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
an	1:0,0,0,0
urticarial	1:0,0,0,0
wheal	1:0,0,0,0
surrounded	1:0,0,0,0
zone	1:0,0,0,0
ery'	1:0,0,0,0
pneumonia.	1:0,0,0,0
successful	1:0,0,0,0
cases	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
puerperal	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
sepsis	1:0,0,0,0
intravenous	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
thema.	1:0,0,0,0
septicemia,	1:0,0,0,0;1:0,0,0,0
using	1:0,0,0,0
daily	1:0,0,0,0
50-010.	1:0,0,0,0
50-cc.	1:0,0,0,0
double-end	1:0,0,0,0
vial	1:0,0,0,0
one	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
complete	1:0,0,0,0
ly	1:0,0,0,0
v	1:0,0,0,0
le	1:0,0,0,0
travenous	1:0,0,0,0
outfit	1:0,0,0,0
for	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
intramuscular	1:0,0,0,0;1:0,0,0,0
eye	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
evert	1:0,0,0,0;1:0,0,0,0
lower	1:0,0,0,0
lid	1:0,0,0,0;1:0,0,0,0
as	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
high	1:0,0,0,0
200	1:0,0,0,0
400	1:0,0,0,0
total	1:0,0,0,0
how	1:0,0,0,0
prepared	1:0,0,0,0
injections.	1:0,0,0,0
dosage	1:0,0,0,0;1:0,0,0,0
1000	1:0,0,0,0
1200	1:0,0,0,0
cc.'	1:0,0,0,0
place	1:0,0,0,0
few	1:0,0,0,0;1:0,0,0,0
drops	1:0,0,0,0;1:0,0,0,0
material	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
on	1:0,0,0,0
conjunc'	1:0,0,0,0
polyvalent	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
uncon	1:0,0,0,0
tiva.	1:0,0,0,0
release	1:0,0,0,0
eye.	1:0,0,0,0;1:0,0,0,0
during	1:0,0,0,0
following	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
oncentrated	1:0,0,0,0
centrated	1:0,0,0,0
horses	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
highly	1:0,0,0,0;1:0,0,0,0
immunized	1:0,0,0,0
ic	1:0,0,0,0;1:0,0,0,0
10-cc.	1:0,0,0,0;1:0,0,0,0
syringes.	1:0,0,0,0
precautions	1:0,0,0,0
minutes	1:0,0,0,0
occasionally	1:0,0,0,0
both	1:0,0,0,0
lids	1:0,0,0,0
compare	1:0,0,0,0
jections	1:0,0,0,0
selected	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
virulent	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
strains	1:0,0,0,0
streptococci,	1:0,0,0,0
tested	1:0,0,0,0
untested	1:0,0,0,0
78.	1:0,0,0,0
glass-encased	1:0,0,0,0
sterjjc	1:0,0,0,0
needle	1:0,0,0,0
viridans.	1:0,0,0,0
fantus*',	1:0,0,0,0
states	1:0,0,0,0
“in	1:0,0,0,0
number	1:0,0,0,0
diseases,	1:0,0,0,0
co	1:0,0,0,0
ncentrated	1:0,0,0,0
congestion	1:0,0,0,0
conjunctival	1:0,0,0,0
vessels,	1:0,0,0,0
lacrimation	1:0,0,0,0
concentrated	1:0,0,0,0;1:0,0,0,0
ob	1:0,0,0,0
therapy	1:0,0,0,0
life	1:0,0,0,0
saving	1:0,0,0,0
hence	1:0,0,0,0
obligatory;	1:0,0,0,0
some	1:0,0,0,0
itching.	1:0,0,0,0
apply	1:0,0,0,0
epinephrine	1:0,0,0,0
solu'	1:0,0,0,0
tained	1:0,0,0,0;1:0,0,0,0
separating	1:0,0,0,0
refining	1:0,0,0,0
globulins	1:0,0,0,0
con	1:0,0,0,0
instances	1:0,0,0,0
injection	1:0,0,0,0;1:0,0,0,0
tion	1:0,0,0,0
1:1000	1:0,0,0,0
immediately	1:0,0,0,0
showing	1:0,0,0,0
posi	1:0,0,0,0
.—	1:0,0,0,0
these	1:0,0,0,0;1:0,0,0,0
products	1:0,0,0,0
are	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
he	1:0,0,0,0
used	1:0,0,0,0;1:0,0,0,0
only	1:0,0,0,0;1:0,0,0,0
polyvalent.	1:0,0,0,0
te	1:0,0,0,0
mode	1:0,0,0,0
administration	1:0,0,0,0;1:0,0,0,0
which	1:0,0,0,0
therapeutic	1:0,0,0,0;1:0,0,0,0
under	1:0,0,0,0
direction	1:0,0,0,0
physician.	1:0,0,0,0
tive	1:0,0,0,0
reaction.	1:0,0,0,0
results	1:0,0,0,0;1:0,0,0,0
can	1:0,0,0,0
obtained.	1:0,0,0,0
some—fortunately	1:0,0,0,0
rare	1:0,0,0,0
cultures	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
streptococci	1:0,0,0,0
immuni	1:0,0,0,0
—cases,	1:0,0,0,0
serious	1:0,0,0,0
sickness	1:0,0,0,0
even	1:0,0,0,0
death	1:0,0,0,0
may	1:0,0,0,0;1:0,0,0,0
result	1:0,0,0,0
zation	1:0,0,0,0
obtained	1:0,0,0,0
from	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
wide	1:0,0,0,0
variety	1:0,0,0,0
remainder	1:0,0,0,0
administration,	1:0,0,0,0
particularly	1:0,0,0,0;1:0,0,0,0
when	1:0,0,0,0
im	1:0,0,0,0
severe	1:0,0,0,0
fatal	1:0,0,0,0;1:0,0,0,0
human	1:0,0,0,0
pasteur*	1:0,0,0,0
first	1:0,0,0,0
cultivated	1:0,0,0,0
1878	1:0,0,0,0
preliminary	1:0,0,0,0
desensitization.	1:0,0,0,0
completion	1:0,0,0,0
properly	1:0,0,0,0
given	1:0,0,0,0;1:0,0,0,0
route.”	1:0,0,0,0
including	1:0,0,0,0
sepsis,	1:0,0,0,0;1:0,0,0,0
erysipelas,	1:0,0,0,0
many	1:0,0,0,0
years	1:0,0,0,0
attempts	1:0,0,0,0
have	1:0,0,0,0
made	1:0,0,0,0;1:0,0,0,0
desensitizing	1:0,0,0,0
accomplished	1:0,0,0,0
septic	1:0,0,0,0;1:0,0,0,0
sore	1:0,0,0,0;1:0,0,0,0
throat,	1:0,0,0,0;1:0,0,0,0
pneumonia,	1:0,0,0,0;1:0,0,0,0
mastoiditis,	1:0,0,0,0
menin	1:0,0,0,0
important	1:0,0,0,0
therefore	1:0,0,0,0
tests	1:0,0,0,0
sen	1:0,0,0,0
comhat	1:0,0,0,0
dilution	1:0,0,0,0;1:0,0,0,0
gitis,	1:0,0,0,0
etc.	1:0,0,0,0
sitivity	1:0,0,0,0
made.	1:0,0,0,0
outline	1:0,0,0,0
1897	1:0,0,0,0
marmorek*	1:0,0,0,0
produced	1:0,0,0,0
was	1:0,0,0,0
sup	1:0,0,0,0
supported	1:0,0,0,0
current	1:0,0,0,0
literature.	1:0,0,0,0
no	1:0,0,0,0
mention	1:0,0,0,0
posedly	1:0,0,0,0
valuable	1:0,0,0,0
all	1:0,0,0,0
types	1:0,0,0,0
virulence	1:0,0,0,0
original	1:0,0,0,0
scratch	1:0,0,0,0
because	1:0,0,0,0
its	1:0,0,0,0
limited	1:0,0,0,0
references	1:0,0,0,0
infections,	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
recent	1:0,0,0,0
investigation*	1:0,0,0,0
tococci	1:0,0,0,0
enhanced	1:0,0,0,0;1:0,0,0,0
repeated	1:0,0,0,0
passages	1:0,0,0,0
through	1:0,0,0,0
necessity	1:0,0,0,0
shown	1:0,0,0,0;1:0,0,0,0
early	1:0,0,0,0;1:0,0,0,0
antitoxic	1:0,0,0,0
mice.	1:0,0,0,0
key	1:0,0,0,0
strains,	1:0,0,0,0;1:0,0,0,0
immunization	1:0,0,0,0
tests.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
1.	1:0,0,0,0
pasteur,‘l.,	1:0,0,0,0
bull.acad.de	1:0,0,0,0
med.,	1:0,0,0,0
paris	1:0,0,0,0
271,*79	1:0,0,0,0
44:	1:0,0,0,0
tococcic	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
there	1:0,0,0,0
reduction	1:0,0,0,0
their	1:0,0,0,0
mortality	1:0,0,0,0
residual	1:0,0,0,0
pathologic	1:0,0,0,0
changes.	1:0,0,0,0
antigenic	1:0,0,0,0
power	1:0,0,0,0
produce	1:0,0,0,0
protective	1:0,0,0,0
antibodies	1:0,0,0,0
2.	1:0,0,0,0
marmorek,	1:0,0,0,0
a.,	1:0,0,0,0
ann.inst.pasteur	1:0,0,0,0
9:	1:0,0,0,0
593,*97	1:0,0,0,0
against	1:0,0,0,0;1:0,0,0,0
3.	1:0,0,0,0
dennis,	1:0,0,0,0
e.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
w.,	1:0,0,0,0;1:0,0,0,0
proc.soc.exper.biol.6^	1:0,0,0,0
med.	1:0,0,0,0
35;	1:0,0,0,0
103,	1:0,0,0,0
oct.*36;	1:0,0,0,0
clinical	1:0,0,0,0
indications	1:0,0,0,0
animal	1:0,0,0,0
protection	1:0,0,0,0;1:0,0,0,0
stamp,	1:0,0,0,0
t.	1:0,0,0,0
c.,	1:0,0,0,0;1:0,0,0,0
hendry,	1:0,0,0,0
b.,	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
lancet	1:0,0,0,0
257,	1:0,0,0,0
jan.	1:0,0,0,0
i:	1:0,0,0,0
30,	1:0,0,0,0
’37;	1:0,0,0,0
rosenow,	1:0,0,0,0
heilman,	1:0,0,0,0
f.	1:0,0,0,0
r.,	1:0,0,0,0
am.j.clin.	1:0,0,0,0
antistrep	1:0,0,0,0;1:0,0,0,0
**for	1:0,0,0,0
th	1:0,0,0,0
conservation	1:0,0,0,0
life*'	1:0,0,0,0
standardization	1:0,0,0,0
path.	1:0,0,0,0
s;	1:0,0,0,0
17,	1:0,0,0,0
jan.'38;	1:0,0,0,0
loewenthal,	1:0,0,0,0
h.,	1:0,0,0,0;1:0,0,0,0
brit.j.exper.path.	1:0,0,0,0
indicated	1:0,0,0,0
19:	1:0,0,0,0
143.	1:0,0,0,0
april	1:0,0,0,0
’38;	1:0,0,0,0
lash,	1:0,0,0,0
a.	1:0,0,0,0;1:0,0,0,0
f.,	1:0,0,0,0;1:0,0,0,0
j.a.m.a.	1:0,0,0,0;1:0,0,0,0
jio;	1:0,0,0,0
1988.	1:0,0,0,0
specific	1:0,0,0,0
acute	1:0,0,0,0;1:0,0,0,0
primary	1:0,0,0,0
secondary	1:0,0,0,0
potency	1:0,0,0,0;1:0,0,0,0
poly	1:0,0,0,0
june	1:0,0,0,0;1:0,0,0,0
11,	1:0,0,0,0
’38	1:0,0,0,0
associated	1:0,0,0,0
strepto	1:0,0,0,0
valent	1:0,0,0,0
determined	1:0,0,0,0
mouse	1:0,0,0,0;1:0,0,0,0
4.	1:0,0,0,0
williams,	1:0,0,0,0
p.	1:0,0,0,0;1:0,0,0,0
am.j.obst.6?	1:0,0,0,0
gynec.	1:0,0,0,0;1:0,0,0,0
636,	1:0,0,0,0
dec.	1:0,0,0,0
*22	1:0,0,0,0
4:	1:0,0,0,0;1:0,0,0,0
coccus	1:0,0,0,0
bacteriemia	1:0,0,0,0
pyemia	1:0,0,0,0
occurring	1:0,0,0,0
standard	1:0,0,0,0
5.	1:0,0,0,0
bailey,	1:0,0,0,0
am.j.obst.6^	1:0,0,0,0
7;	1:0,0,0,0
658,	1:0,0,0,0
*24;	1:0,0,0,0
cont.	1:0,0,0,0
7,	1:0,0,0,0
8:	1:0,0,0,0
such	1:0,0,0,0
each	1:0,0,0,0
protects	1:0,0,0,0
july	1:0,0,0,0
’24	1:0,0,0,0
meningitis,	1:0,0,0,0
cellulitis,	1:0,0,0,0
white	1:0,0,0,0
at	1:0,0,0,0
least	1:0,0,0,0
10,000	1:0,0,0,0
sinusitis,	1:0,0,0,0
otitis,	1:0,0,0,0
empyemia	1:0,0,0,0
post-operative	1:0,0,0,0
infec	1:0,0,0,0
6.	1:0,0,0,0
hansen.	1:0,0,0,0
brit.m.j.	1:0,0,0,0
25,	1:0,0,0,0
feb.	1:0,0,0,0
12,*21	1:0,0,0,0
(epitome)	1:0,0,0,0
minimum	1:0,0,0,0
culture.	1:0,0,0,0
1:	1:0,0,0,0
tions	1:0,0,0,0
(a	1:0,0,0,0;1:0,0,0,0
group	1:0,0,0,0;1:0,0,0,0
usually	1:0,0,0,0;1:0,0,0,0
caused	1:0,0,0,0;1:0,0,0,0
tococci);	1:0,0,0,0
circulatory	1:0,0,0,0
heart	1:0,0,0,0
7.	1:0,0,0,0
rosenberg,	1:0,0,0,0
l.,	1:0,0,0,0;1:0,0,0,0
nottley,	1:0,0,0,0
h.	1:0,0,0,0;1:0,0,0,0
ann.int.med.	1:0,0,0,0
1154,	1:0,0,0,0
march	1:0,0,0,0
’31	1:0,0,0,0
u	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
lfo	1:0,0,0,0
d	1:0,0,0,0;1:0,0,0,0
b	1:0,0,0,0;1:0,0,0,0
io	1:0,0,0,0
lo	1:0,0,0,0
g	1:0,0,0,0
l	1:0,0,0,0;1:0,0,0,0
ie	1:0,0,0,0
genito-urinary	1:0,0,0,0
rheumatic	1:0,0,0,0
conditions	1:0,0,0,0
viridans).	1:0,0,0,0
8.	1:0,0,0,0
amoss,	1:0,0,0,0
craven,	1:0,0,0,0
jr.,	1:0,0,0,0
j.clin.investigation	1:0,0,0,0
essential	1:0,0,0,0
success	1:0,0,0,0
sharp	1:0,0,0,0
&	1:0,0,0,0
dohme	1:0,0,0,0
885,	1:0,0,0,0
sept.	1:0,0,0,0
’33	1:0,0,0,0
22:	1:0,0,0,0
streptococcic	1:0,0,0,0
williams*,	1:0,0,0,0
bailey*	1:0,0,0,0
hansen*	1:0,0,0,0
report	1:0,0,0,0
beneficial	1:0,0,0,0
require	1:0,0,0,0
9.	1:0,0,0,0
kolmer,	1:0,0,0,0
j.	1:0,0,0,0
a.:	1:0,0,0,0
infection,	1:0,0,0,0
immunity,	1:0,0,0,0
biologic	1:0,0,0,0
therapy,	1:0,0,0,0
h	1:0,0,0,0;1:0,0,0,0
lp	1:0,0,0,0
ia	1:0,0,0,0
,	1:0,0,0,0
.	1:0,0,0,0;1:0,0,0,0;1:0,0,0,0
infection	1:0,0,0,0
possible	1:0,0,0,0
pyemia.	1:0,0,0,0
general,	1:0,0,0,0
philadelphia,	1:0,0,0,0
w.	1:0,0,0,0
b.	1:0,0,0,0
saunders	1:0,0,0,0
co.,	1:0,0,0,0
ed.	1:0,0,0,0
3,	1:0,0,0,0
1924,	1:0,0,0,0
893	1:0,0,0,0
•test	1:0,0,0,0
1:10	1:0,0,0,0
physiologic	1:0,0,0,0
preferably	1:0,0,0,0
injection.	1:0,0,0,0
68706c	1:0,0,0,0
saline	1:0,0,0,0
normal	1:0,0,0,0
equine	1:0,0,0,0
10.	1:0,0,0,0
fantus,	1:0,0,0,0
j07;	1:0,0,0,0
1717,	1:0,0,0,0
nov.	1:0,0,0,0
21,*36	1:0,0,0,0
printed	1:0,0,0,0
u.	1:0,0,0,0
s.	1:0,0,0,0
4	1:0,0,0,0